Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT05145816

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	University of Texas Southwestern Medical Center
Enrollment	37 participants

Key Eligibility Criteria

Inclusion (54)

- Participants medically diagnosed with relapsed or refractory Amyloid Light Chain Amyloidosis (AL amyloidosis) with one or more line of treatment as below:
- Must have received a proteosome inhibitor, alkylator and anti-cluster of differentiation 38 (CD38) antibody (e.g., daratumumab - for patients who were eligible to receive in newly diagnosed AL Amyloidosis) and autologous stem cell transplant (for transplant eligible candidates).
- OR
- Failed treatment and/or intolerant/ineligible for above agents
- NOTE: Patients who fail to achieve Partial Hematological Response or better after 2 cycles of induction therapy for newly diagnosed AL Amyloidosis are also eligible.

... and 49 more (see full listing online)

Exclusion (30)

- Patients previously treated for active symptomatic multiple myeloma.
- Any corneal disease except for mild epithelial punctate keratopathy.
- Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
- Patients eligible for autologous stem cell transplantation (ASCT).
- Evidence of significant cardiovascular condition as specified below:

... and 25 more (see full listing online)

Locations (3 total)

Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States